Public Act 099-0843 Public Act 0843 99TH GENERAL ASSEMBLY |
Public Act 099-0843 | HB6333 Enrolled | LRB099 18475 NHT 42851 b |
|
| AN ACT concerning education.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The School Code is amended by changing Section | 22-30 as follows:
| (105 ILCS 5/22-30)
| Sec. 22-30. Self-administration and self-carry of asthma | medication and epinephrine auto-injectors; administration of | undesignated epinephrine auto-injectors; administration of an | opioid antagonist ; asthma episode emergency response protocol .
| (a) For the purpose of this Section only, the following | terms shall have the meanings set forth below:
| "Asthma action plan" means a written plan developed with a | pupil's medical provider to help control the pupil's asthma. | The goal of an asthma action plan is to reduce or prevent | flare-ups and emergency department visits through day-to-day | management and to serve as a student-specific document to be | referenced in the event of an asthma episode. | "Asthma episode emergency response protocol" means a | procedure to provide assistance to a pupil experiencing | symptoms of wheezing, coughing, shortness of breath, chest | tightness, or breathing difficulty. | "Asthma inhaler" means a quick reliever asthma inhaler. |
| "Epinephrine auto-injector" means a single-use device used | for the automatic injection of a pre-measured dose of | epinephrine into the human body.
| "Asthma medication" means a medicine, prescribed by (i) a | physician
licensed to practice medicine in all its branches,
| (ii) a licensed physician assistant with prescriptive | authority, or (iii) a licensed advanced practice
nurse with | prescriptive authority
for a pupil that pertains to the pupil's
| asthma and that has an individual prescription label.
| "Opioid antagonist" means a drug that binds to opioid | receptors and blocks or inhibits the effect of opioids acting | on those receptors, including, but not limited to, naloxone | hydrochloride or any other similarly acting drug approved by | the U.S. Food and Drug Administration. | "School nurse" means a registered nurse working in a school | with or without licensure endorsed in school nursing. | "Self-administration" means a pupil's discretionary use of | his or
her prescribed asthma medication or epinephrine | auto-injector.
| "Self-carry" means a pupil's ability to carry his or her | prescribed asthma medication or epinephrine auto-injector. | "Standing protocol" may be issued by (i) a physician | licensed to practice medicine in all its branches, (ii) a | licensed physician assistant with prescriptive authority, or | (iii) a licensed advanced practice nurse with prescriptive | authority . |
| "Trained personnel" means any school employee or volunteer | personnel authorized in Sections 10-22.34, 10-22.34a, and | 10-22.34b of this Code who has completed training under | subsection (g) of this Section to recognize and respond to | anaphylaxis. | "Undesignated epinephrine auto-injector" means an | epinephrine auto-injector prescribed in the name of a school | district, public school, or nonpublic school. | (b) A school, whether public or nonpublic, must permit the
| self-administration and self-carry of asthma
medication by a | pupil with asthma or the self-administration and self-carry of | an epinephrine auto-injector by a pupil, provided that:
| (1) the parents or
guardians of the pupil provide to | the school (i) written
authorization from the parents or | guardians for (A) the self-administration and self-carry | of asthma medication or (B) the self-carry of asthma | medication or (ii) for (A) the self-administration and | self-carry of an epinephrine auto-injector or (B) the | self-carry of an epinephrine auto-injector, written | authorization from the pupil's physician, physician | assistant, or advanced practice nurse; and
| (2) the
parents or guardians of the pupil provide to | the school (i) the prescription label, which must contain | the name of the asthma medication, the prescribed dosage, | and the time at which or circumstances under which the | asthma medication is to be administered, or (ii) for the |
| self-administration or self-carry of an epinephrine | auto-injector, a
written
statement from the pupil's | physician, physician assistant, or advanced practice
nurse | containing
the following information:
| (A) the name and purpose of the epinephrine | auto-injector;
| (B) the prescribed dosage; and
| (C) the time or times at which or the special | circumstances
under which the epinephrine | auto-injector is to be administered.
| The information provided shall be kept on file in the office of | the school
nurse or,
in the absence of a school nurse, the | school's administrator.
| (b-5) A school district, public school, or nonpublic school | may authorize the provision of a student-specific or | undesignated epinephrine auto-injector to a student or any | personnel authorized under a student's Individual Health Care | Action Plan, Illinois Food Allergy Emergency Action Plan and | Treatment Authorization Form, or plan pursuant to Section 504 | of the federal Rehabilitation Act of 1973 to administer an | epinephrine auto-injector to the student, that meets the | student's prescription on file. | (b-10) The school district, public school, or nonpublic | school may authorize a school nurse or trained personnel to do | the following: (i) provide an undesignated epinephrine | auto-injector to a student for self-administration only or any |
| personnel authorized under a student's Individual Health Care | Action Plan, Illinois Food Allergy Emergency Action Plan and | Treatment Authorization Form, or plan pursuant to Section 504 | of the federal Rehabilitation Act of 1973 to administer to the | student, that meets the student's prescription on file; (ii) | administer an undesignated epinephrine auto-injector that | meets the prescription on file to any student who has an | Individual Health Care Action Plan, Illinois Food Allergy | Emergency Action Plan and Treatment Authorization Form, or plan | pursuant to Section 504 of the federal Rehabilitation Act of | 1973 that authorizes the use of an epinephrine auto-injector; | (iii) administer an undesignated epinephrine auto-injector to | any person that the school nurse or trained personnel in good | faith believes is having an anaphylactic reaction; and (iv) | administer an opioid antagonist to any person that the school | nurse or trained personnel in good faith believes is having an | opioid overdose. | (c) The school district, public school, or nonpublic school | must inform the parents or
guardians of the
pupil, in writing, | that the school district, public school, or nonpublic school | and its
employees and
agents, including a physician, physician | assistant, or advanced practice nurse providing standing | protocol or prescription for school epinephrine | auto-injectors,
are to incur no liability or professional | discipline, except for willful and wanton conduct, as a result
| of any injury arising from the
administration of asthma |
| medication, an epinephrine auto-injector, or an opioid | antagonist regardless of whether authorization was given by the | pupil's parents or guardians or by the pupil's physician, | physician assistant, or advanced practice nurse. The parents or | guardians
of the pupil must sign a statement acknowledging that | the school district, public school,
or nonpublic school and its | employees and agents are to incur no liability, except for | willful and wanton
conduct, as a result of any injury arising
| from the
administration of asthma medication, an epinephrine | auto-injector, or an opioid antagonist regardless of whether | authorization was given by the pupil's parents or guardians or | by the pupil's physician, physician assistant, or advanced | practice nurse and that the parents or
guardians must indemnify | and hold harmless the school district, public school, or | nonpublic
school and
its
employees and agents against any | claims, except a claim based on willful and
wanton conduct, | arising out of the
administration of asthma medication, an | epinephrine auto-injector, or an opioid antagonist regardless | of whether authorization was given by the pupil's parents or | guardians or by the pupil's physician, physician assistant, or | advanced practice nurse. | (c-5) When a school nurse or trained personnel administers | an undesignated epinephrine auto-injector to a person whom the | school nurse or trained personnel in good faith believes is | having an anaphylactic reaction , or administers an opioid | antagonist to a person whom the school nurse or trained |
| personnel in good faith believes is having an opioid overdose, | notwithstanding the lack of notice to the parents or guardians | of the pupil or the absence of the parents or guardians signed | statement acknowledging no liability, except for willful and | wanton conduct, the school district, public school, or | nonpublic school and its employees and agents, and a physician, | a physician assistant, or an advanced practice nurse providing | standing protocol or prescription for undesignated epinephrine | auto-injectors, are to incur no liability or professional | discipline, except for willful and wanton conduct, as a result | of any injury arising from the use of an undesignated | epinephrine auto-injector or the use of an opioid antagonist | regardless of whether authorization was given by the pupil's | parents or guardians or by the pupil's physician, physician | assistant, or advanced practice nurse.
| (d) The permission for self-administration and self-carry | of asthma medication or the self-administration and self-carry | of an epinephrine auto-injector is effective
for the school | year for which it is granted and shall be renewed each
| subsequent school year upon fulfillment of the requirements of | this
Section.
| (e) Provided that the requirements of this Section are | fulfilled, a
pupil with asthma may self-administer and | self-carry his or her asthma medication or a pupil may | self-administer and self-carry an epinephrine auto-injector | (i) while in
school, (ii) while at a school-sponsored activity, |
| (iii) while under the
supervision of
school personnel, or (iv) | before or after normal school activities, such
as while in | before-school or after-school care on school-operated
| property.
| (e-5) Provided that the requirements of this Section are | fulfilled, a school nurse or trained personnel may administer | an undesignated epinephrine auto-injector to any person whom | the school nurse or trained personnel in good faith believes to | be having an anaphylactic reaction (i) while in school, (ii) | while at a school-sponsored activity, (iii) while under the | supervision of school personnel, or (iv) before or after normal | school activities, such
as while in before-school or | after-school care on school-operated property. A school nurse | or trained personnel may carry undesignated epinephrine | auto-injectors on his or her person while in school or at a | school-sponsored activity. | (e-10) Provided that the requirements of this Section are | fulfilled, a school nurse or trained personnel may administer | an opioid antagonist to any person whom the school nurse or | trained personnel in good faith believes to be having an opioid | overdose (i) while in school, (ii) while at a school-sponsored | activity, (iii) while under the supervision of school | personnel, or (iv) before or after normal school activities, | such as while in before-school or after-school care on | school-operated property. A school nurse or trained personnel | may carry an opioid antagonist on their person while in school |
| or at a school-sponsored activity. | (f) The school district, public school, or nonpublic school | may maintain a supply of undesignated epinephrine | auto-injectors in any secure location where an allergic person | is most at risk, including, but not limited to, classrooms and | lunchrooms. A physician, a physician assistant who has been | delegated prescriptive authority in accordance with Section | 7.5 of the Physician Assistant Practice Act of 1987, or an | advanced practice nurse who has been delegated prescriptive | authority in accordance with Section 65-40 of the Nurse | Practice Act may prescribe undesignated epinephrine | auto-injectors in the name of the school district, public | school, or nonpublic school to be maintained for use when | necessary. Any supply of epinephrine auto-injectors shall be | maintained in accordance with the manufacturer's instructions. | The school district, public school, or nonpublic school may | maintain a supply of an opioid antagonist in any secure | location where an individual may have an opioid overdose. A | health care professional who has been delegated prescriptive | authority for opioid antagonists in accordance with Section | 5-23 of the Alcoholism and Other Drug Abuse and Dependency Act | may prescribe opioid antagonists in the name of the school | district, public school, or nonpublic school, to be maintained | for use when necessary. Any supply of opioid antagonists shall | be maintained in accordance with the manufacturer's | instructions. |
| (f-5) Upon any administration of an epinephrine | auto-injector, a school district, public school, or nonpublic | school must immediately activate the EMS system and notify the | student's parent, guardian, or emergency contact, if known. | Upon any administration of an opioid antagonist, a school | district, public school, or nonpublic school must immediately | activate the EMS system and notify the student's parent, | guardian, or emergency contact, if known. | (f-10) Within 24 hours of the administration of an | undesignated epinephrine auto-injector, a school district, | public school, or nonpublic school must notify the physician, | physician assistant, or advanced advance practice nurse who | provided the standing protocol or prescription for the | undesignated epinephrine auto-injector of its use. | Within 24 hours after the administration of an opioid | antagonist, a school district, public school, or nonpublic | school must notify the health care professional who provided | the prescription for the opioid antagonist of its use. | (g) Prior to the administration of an undesignated | epinephrine auto-injector, trained personnel must submit to | their his or her school's administration proof of completion of | a training curriculum to recognize and respond to anaphylaxis | that meets the requirements of subsection (h) of this Section. | Training must be completed annually. Trained personnel must | also submit to their his or her school's administration proof | of cardiopulmonary resuscitation and automated external |
| defibrillator certification. The school district, public | school, or nonpublic school must maintain records related to | the training curriculum and trained personnel. | Prior to the administration of an opioid antagonist, | trained personnel must submit to their school's administration | proof of completion of a training curriculum to recognize and | respond to an opioid overdose, which curriculum must meet the | requirements of subsection (h-5) of this Section. Training must | be completed annually. Trained personnel must also submit to | the school's administration proof of cardiopulmonary | resuscitation and automated external defibrillator | certification. The school district, public school, or | nonpublic school must maintain records relating to the training | curriculum and the trained personnel. | (h) A training curriculum to recognize and respond to | anaphylaxis, including the administration of an undesignated | epinephrine auto-injector, may be conducted online or in | person. It must include, but is not limited to: | (1) how to recognize symptoms of an allergic reaction; | (2) a review of high-risk areas within the school and | its related facilities; | (3) steps to take to prevent exposure to allergens; | (4) how to respond to an emergency involving an | allergic reaction; | (5) how to administer an epinephrine auto-injector; | (6) how to respond to a student with a known allergy as |
| well as a student with a previously unknown allergy; | (7) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an | epinephrine auto-injector; and | (8) other criteria as determined in rules adopted | pursuant to this Section. | In consultation with statewide professional organizations | representing physicians licensed to practice medicine in all of | its branches, registered nurses, and school nurses, the State | Board of Education shall make available resource materials | consistent with criteria in this subsection (h) for educating | trained personnel to recognize and respond to anaphylaxis. The | State Board may take into consideration the curriculum on this | subject developed by other states, as well as any other | curricular materials suggested by medical experts and other | groups that work on life-threatening allergy issues. The State | Board is not required to create new resource materials. The | State Board shall make these resource materials available on | its Internet website. | (h-5) A training curriculum to recognize and respond to an | opioid overdose, including the administration of an opioid | antagonist, may be conducted online or in person. The training | must comply with any training requirements under Section 5-23 | of the Alcoholism and Other Drug Abuse and Dependency Act and | the corresponding rules. It must include, but is not limited | to: |
| (1) how to recognize symptoms of an opioid overdose; | (2) information on drug overdose prevention and | recognition; | (3) how to perform rescue breathing and resuscitation; | (4) how to respond to an emergency involving an opioid | overdose; | (5) opioid antagonist dosage and administration; | (6) the importance of calling 911; | (7) care for the overdose victim after administration | of the overdose antagonist; | (8) a test demonstrating competency of the knowledge | required to recognize an opioid overdose and administer a | dose of an opioid antagonist; and | (9) other criteria as determined in rules adopted | pursuant to this Section. | (i) Within 3 days after the administration of an | undesignated epinephrine auto-injector by a school nurse, | trained personnel, or a student at a school or school-sponsored | activity, the school must report to the State Board in a form | and manner prescribed by the State Board the following | information: | (1) age and type of person receiving epinephrine | (student, staff, visitor); | (2) any previously known diagnosis of a severe allergy; | (3) trigger that precipitated allergic episode; | (4) location where symptoms developed; |
| (5) number of doses administered; | (6) type of person administering epinephrine (school | nurse, trained personnel, student); and | (7) any other information required by the State Board. | (i-5) Within 3 days after the administration of an opioid | antagonist by a school nurse or trained personnel, the school | must report to the State Board, in a form and manner prescribed | by the State Board, the following information: | (1) the age and type of person receiving the opioid | antagonist (student, staff, or visitor); | (2) the location where symptoms developed; | (3) the type of person administering the opioid | antagonist (school nurse or trained personnel); and | (4) any other information required by the State Board. | (j) By October 1, 2015 and every year thereafter, the State | Board shall submit a report to the General Assembly identifying | the frequency and circumstances of epinephrine administration | during the preceding academic year. This report shall be | published on the State Board's Internet website on the date the | report is delivered to the General Assembly. | (j-5) Annually, each school district, public school, | charter school, or nonpublic school shall request an asthma | action plan from the parents or guardians of a pupil with | asthma. If provided, the asthma action plan must be kept on | file in the office of the school nurse or, in the absence of a | school nurse, the school administrator. Copies of the asthma |
| action plan may be distributed to appropriate school staff who | interact with the pupil on a regular basis, and, if applicable, | may be attached to the pupil's federal Section 504 plan or | individualized education program plan. | (j-10) To assist schools with emergency response | procedures for asthma, the State Board of Education, in | consultation with statewide professional organizations with | expertise in asthma management and a statewide organization | representing school administrators, shall develop a model | asthma episode emergency response protocol before September 1, | 2016. Each school district, charter school, and nonpublic | school shall adopt an asthma episode emergency response | protocol before January 1, 2017 that includes all of the | components of the State Board's model protocol. | (j-15) Every 2 years, school personnel who work with pupils | shall complete an in-person or online training program on the | management of asthma, the prevention of asthma symptoms, and | emergency response in the school setting. In consultation with | statewide professional organizations with expertise in asthma | management, the State Board of Education shall make available | resource materials for educating school personnel about asthma | and emergency response in the school setting. | On or before October 1, 2016 and every year thereafter, the | State Board shall submit a report to the General Assembly and | the Department of Public Health identifying the frequency and | circumstances of opioid antagonist administration during the |
| preceding academic year. This report shall be published on the | State Board's Internet website on the date the report is | delivered to the General Assembly. | (k) The State Board may adopt rules necessary to implement | this Section. | (Source: P.A. 98-795, eff. 8-1-14; 99-173, eff. 7-29-15; | 99-480, eff. 9-9-15; revised 10-13-15.)
| Section 99. Effective date. This Act takes effect upon | becoming law.
|
Effective Date: 8/19/2016
|